124 research outputs found
Replication Data for: Endogenous Price Commitment, Sticky and Leadership Pricing: Evidence from the Italian Petrol Market
No full textThe do-file contains the code to replicate "Endogenous Price Commitment, Sticky and Leadership Pricing: Evidence from the Italian Petrol Market", published in the International Journal of Industrial Organization, vol. 40(C), pages 32-48, by Patrick Andreoli-Versbach and Jens-Uwe Franck.
Contact author is Patrick Andreoli-Versbach. E-Mail: [email protected]
Replication Data for: Endogenous Price Commitment, Sticky and Leadership Pricing: Evidence from the Italian Petrol Market
No full textThe do-file contains the code to replicate "Endogenous Price Commitment, Sticky and Leadership Pricing: Evidence from the Italian Petrol Market", published in the International Journal of Industrial Organization, vol. 40(C), pages 32-48, by Patrick Andreoli-Versbach and Jens-Uwe Franck.
Contact author is Patrick Andreoli-Versbach. E-Mail: [email protected]
LOW VITAMIN D LEVELS ARE COMMON IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS): A ROLE IN THE PATHOGENESIS OF THE DISEASE?
No full textLow levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease
No full textThe aim of this study was to assess vitamin D (vit.D) levels in patients with primary antiphospholipid syndrome (PAPS), the association between hypovitaminosis D and clinical manifestations, and the effect of vit.D supplementation on serum levels. Vit.D serum levels of 115 PAPS patients, classified according to the 2006 revised criteria at the Rheumatology Department, Brescia, and of 128 voluntary healthy donors (NHD) were tested in collaboration with DiaSorin (Saluggia, Italy) using the LIAISON® chemiluminescent immunoassay. Clinical data were derived from clinical charts. Vit.D deficiency was more prevalent in PAPS than NHD (17% vs 5%). During the summer, vit.D levels were lower in PAPS than NHD (median 28 vs 40.1 ng/mL, P<0.01). PAPS were subdivided according to clinical characteristics (thrombotic vs obstetric). Both groups had lower vit.D levels compared to NHD. Thrombotic PAPS had significantly lower levels than obstetric PAPS (median 20.8 vs 33.3, P<0.01). Sixteen patients (14%) received oral 25-OH vit.D supplementation (average 400 UI/die), but 63% of them did not reach serum levels above 30 ng/mL. PAPS showed significantly lower levels of vit.D than NHD. Hypovitaminosis D was seen to cluster in patients with thrombosis which may suggest that the lack of vit.D could be one of the many factors involved in the thrombotic process. Low-dose supplementation did not seem to be effective in a small group of patients
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges.
No full textThe treatment of anti-phospholipid syndrome: A comprehensive clinical approach
No full textAnti-phospholipid syndrome (APS) is an acquired pro-thrombotic autoimmune disease that predisposes to thrombotic events and/or obstetric complications, in the persistent presence of anti-phospholipid antibodies (aPL). Life long moderate-intensity anticoagulation is the option of choice for aPL-positive patients with a previous thrombosis; critical issues concern the management of those with a history of arterial event due to the high rate of recurrence. Alternatives comprise anti-platelet agents and high-intensity anticoagulation. Low dose aspirin (LDASA) and low molecular weight heparin provide the mainstay of the treatment of obstetric APS, allowing a birth rate in 70% of cases. The management of refractory APS, thrombotic as well as obstetric, is highly debated, but an increasing burden of evidence points towards the beneficial effects of multiple treatments. Similarly, a management envisaging multiple drugs (anticoagulation, steroids, plasma exchange and/or intravenous immunoglobulins) is the most effective approach in catastrophic APS. Asymptomatic aPL carriers are at higher risk of thrombotic and obstetric complications compared to the general population, thus potentially benefitting of a pharmacological intervention. LDASA and hydroxychloroquine can be considered as options, in particular in case of high risk aPL profile, concomitant cardiovascular risk factors or associated autoimmune disease. APS is apparently a simple condition, but its multifaceted nature requires a complex and tailored treatment
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive?
No full text- …
